{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:25:09Z","timestamp":1783481109737,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the efficacy of XEN<jats:sup>\u00ae<\/jats:sup>-45 gel stent ab interno implantation for medically uncontrolled uveitic glaucoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective analysis of 25 eyes receiving XEN<jats:sup>\u00ae<\/jats:sup> gel stent for medically uncontrolled uveitic glaucoma from February 2019 to February 2023 with recording of intraocular pressure (IOP) values, ocular hypotensive medication, requirement for revision or secondary surgery and complications. Prerequisites for XEN<jats:sup>\u00ae<\/jats:sup> implantation were a clear cornea, an open iridocorneal angle and an unscarred, mobile conjunctiva at the implantation site. Minimum follow-up required for inclusion was 3\u00a0months. The primary outcome measure was IOP compared to baseline. Complete and qualified success were defined as final IOP of\u2009\u2264\u200918\u00a0mmHg without or with topical antiglaucomatous treatment, respectively. Failure was defined as IOP\u2009&gt;\u200918\u00a0mmHg on two consecutive visits, IOP reduction\u2009&lt;\u200920%, persisting complications from hypotony and open conjunctival bleb revision. Further glaucoma surgical intervention was defined as complete failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean preoperative IOP was 35.3\u2009\u00b1\u200910.9\u00a0mmHg on 2.9\u2009\u00b1\u20090.9 topical antiglaucomatous agents. 19 of 25 patients (76%) received additional oral acetazolamide. 19 eyes were pseudophakic, 5 eyes phakic and 1 aphakic.<\/jats:p>\n                <jats:p>Early postoperatively, mean IOP reduced to 7.7\u2009\u00b1\u20093.0\u00a0mmHg (75.8% reduction). At final follow-up (mean 17.7\u00a0months) mean IOP was 12.0\u2009\u00b1\u20093.8\u00a0mmHg (62.5% reduction) on 0.2\u2009\u00b1\u20090.6 medications.<\/jats:p>\n                <jats:p>Six eyes (24%) required bleb revision at mean 28\u00a0weeks and therefore were categorized as failure. One eye failed despite bleb revision and restart of topical ocular hypotensive medication. Three other eyes (12%) had IOP spikes with uveitis flare-ups. Transient hypotony complications occurred in 32%. At final follow-up, 18 eyes (72%) achieved complete success and one eye (4%) qualified success.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The XEN<jats:sup>\u00ae<\/jats:sup> gel stent effectively reduced IOP in uncontrolled uveitic glaucoma, with 72% complete success. Bleb revision was required in 24%. IOP spikes occurred in 12% despite functioning blebs. Further follow-up is needed to determine long-term outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-023-06254-3","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T10:03:30Z","timestamp":1697709810000},"page":"937-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["XEN\u00ae-45 implantation for refractory uveitic glaucoma"],"prefix":"10.1007","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-0298","authenticated-orcid":false,"given":"Charlotte","family":"Evers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"B\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kallee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Keye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ne\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Philippin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"6254_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jcrs.2014.01.032","volume":"40","author":"RA Lewis","year":"2014","unstructured":"Lewis RA (2014) Ab interno approach to the subconjunctival space using a collagen glaucoma stent. J Cataract Refract Surg 40:1301\u20131306. https:\/\/doi.org\/10.1016\/j.jcrs.2014.01.032","journal-title":"J Cataract Refract Surg"},{"key":"6254_CR2","doi-asserted-by":"publisher","first-page":"5457246","DOI":"10.1155\/2017\/5457246","volume":"2017","author":"A Galal","year":"2017","unstructured":"Galal A, Bilgic A, Eltanamly R, Osman A (2017) XEN Glaucoma implant with Mitomycin C 1-Year Follow-Up: Result and complications. J Ophthalmol 2017:5457246. https:\/\/doi.org\/10.1155\/2017\/5457246","journal-title":"J Ophthalmol"},{"key":"6254_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/eye.2017.162","volume":"32","author":"SZ Tan","year":"2018","unstructured":"Tan SZ, Walkden A, Au L (2018) One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management. Eye (Lond) 32:324\u2013332. https:\/\/doi.org\/10.1038\/eye.2017.162","journal-title":"Eye (Lond)"},{"key":"6254_CR4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00417-019-04251-z","volume":"257","author":"H Reitsamer","year":"2019","unstructured":"Reitsamer H, Sng C, Vera V et al (2019) Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 257:983\u2013996. https:\/\/doi.org\/10.1007\/s00417-019-04251-z","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6254_CR5","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1111\/aos.14886","volume":"100","author":"H Reitsamer","year":"2022","unstructured":"Reitsamer H, Vera V, Ruben S et al (2022) Three-year effectiveness and safety of the XEN gel stent as a solo procedure or in combination with phacoemulsification in open-angle glaucoma: a multicentre study. Acta Ophthalmol 100:e233\u2013e245. https:\/\/doi.org\/10.1111\/aos.14886","journal-title":"Acta Ophthalmol"},{"key":"6254_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/ceo.13463","volume":"47","author":"M Lenzhofer","year":"2019","unstructured":"Lenzhofer M, Kersten-Gomez I, Sheybani A et al (2019) Four-year results of a minimally invasive transscleral glaucoma gel stent implantation in a prospective multi-centre study. Clin Exp Ophthalmol 47:581\u2013587. https:\/\/doi.org\/10.1111\/ceo.13463","journal-title":"Clin Exp Ophthalmol"},{"key":"6254_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12886-020-01764-8","volume":"20","author":"M Schargus","year":"2020","unstructured":"Schargus M, Theilig T, Rehak M et al (2020) Outcome of a single XEN microstent implant for glaucoma patients with different types of glaucoma. BMC Ophthalmol 20:490. https:\/\/doi.org\/10.1186\/s12886-020-01764-8","journal-title":"BMC Ophthalmol"},{"key":"6254_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/ceo.13087","volume":"46","author":"CC Sng","year":"2018","unstructured":"Sng CC, Wang J, Hau S et al (2018) XEN-45 collagen implant for the treatment of uveitic glaucoma. Clin Exp Ophthalmol 46:339\u2013345. https:\/\/doi.org\/10.1111\/ceo.13087","journal-title":"Clin Exp Ophthalmol"},{"key":"6254_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/IJG.0000000000001389","volume":"28","author":"A Qureshi","year":"2019","unstructured":"Qureshi A, Jones NP, Au L (2019) Urgent management of secondary Glaucoma in Uveitis Using the Xen-45 Gel Stent. J Glaucoma 28:1061\u20131066. https:\/\/doi.org\/10.1097\/IJG.0000000000001389","journal-title":"J Glaucoma"},{"key":"6254_CR10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s00417-015-3102-3","volume":"253","author":"A Anton","year":"2015","unstructured":"Anton A, Heinzelmann S, Ne\u00df T et al (2015) Trabeculectomy ab interno with the Trabectome\u00ae as a therapeutic option for uveitic secondary glaucoma. Graefes Arch Clin Exp Ophthalmol 253:1973\u20131978. https:\/\/doi.org\/10.1007\/s00417-015-3102-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6254_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/eye.2015.112","volume":"29","author":"M Pahlitzsch","year":"2015","unstructured":"Pahlitzsch M, Torun N, Gonnermann J et al (2015) Trabeculectomy ab interno (trabectome): yet another possibility in the treatment of uncontrolled glaucomatocyclitic crisis under systemic valganciclovir therapy? Eye (Lond) 29:1335\u20131339. https:\/\/doi.org\/10.1038\/eye.2015.112","journal-title":"Eye (Lond)"},{"key":"6254_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ceo.13639","volume":"48","author":"R Swamy","year":"2020","unstructured":"Swamy R, Francis BA, Akil H et al (2020) Clinical results of ab interno trabeculotomy using the trabectome in patients with uveitic glaucoma. Clin Exp Ophthalmol 48:31\u201336. https:\/\/doi.org\/10.1111\/ceo.13639","journal-title":"Clin Exp Ophthalmol"},{"key":"6254_CR13","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1007\/s10792-021-01977-w","volume":"41","author":"D Kiessling","year":"2021","unstructured":"Kiessling D, Rennings C, Hild M et al (2021) Impact of failed ab-interno trabeculectomy (trabectome) on subsequent XEN45 gel stent implantation in pseudophakic eyes. Int Ophthalmol 41:4047\u20134053. https:\/\/doi.org\/10.1007\/s10792-021-01977-w","journal-title":"Int Ophthalmol"},{"key":"6254_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/00061198-200206000-00005","volume":"11","author":"EM Ceballos","year":"2002","unstructured":"Ceballos EM, Beck AD, Lynn MJ (2002) Trabeculectomy with antiproliferative agents in uveitic glaucoma. J Glaucoma 11:189\u2013196. https:\/\/doi.org\/10.1097\/00061198-200206000-00005","journal-title":"J Glaucoma"},{"key":"6254_CR15","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/s0161-6420(00)00351-1","volume":"107","author":"HM Towler","year":"2000","unstructured":"Towler HM, McCluskey P, Shaer B, Lightman S (2000) Long-term follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucoma. Ophthalmology 107:1822\u20131828. https:\/\/doi.org\/10.1016\/s0161-6420(00)00351-1","journal-title":"Ophthalmology"},{"key":"6254_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/s0002-9394(99)00185-3","volume":"128","author":"P Stavrou","year":"1999","unstructured":"Stavrou P, Murray PI (1999) Long-term follow-up of trabeculectomy without antimetabolites in patients with uveitis. Am J Ophthalmol 128:434\u2013439. https:\/\/doi.org\/10.1016\/s0002-9394(99)00185-3","journal-title":"Am J Ophthalmol"},{"key":"6254_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3129\/canjophthalmol.06-124","volume":"42","author":"J Noble","year":"2007","unstructured":"Noble J, Derzko-Dzulynsky L, Rabinovitch T, Birt C (2007) Outcome of trabeculectomy with intraoperative mitomycin C for uveitic glaucoma. Can J Ophthalmol 42:89\u201394. https:\/\/doi.org\/10.3129\/canjophthalmol.06-124","journal-title":"Can J Ophthalmol"},{"key":"6254_CR18","doi-asserted-by":"publisher","first-page":"e1120","DOI":"10.1111\/aos.15042","volume":"100","author":"FM Wagner","year":"2022","unstructured":"Wagner FM, Schuster AK, Munder A et al (2022) Comparison of subconjunctival microinvasive glaucoma surgery and trabeculectomy. Acta Ophthalmol 100:e1120\u2013e1126. https:\/\/doi.org\/10.1111\/aos.15042","journal-title":"Acta Ophthalmol"},{"key":"6254_CR19","doi-asserted-by":"publisher","first-page":"19337","DOI":"10.1038\/s41598-020-76551-y","volume":"10","author":"T Theilig","year":"2020","unstructured":"Theilig T, Rehak M, Busch C et al (2020) Comparing the efficacy of trabeculectomy and XEN gel microstent implantation for the treatment of primary open-angle glaucoma: a retrospective monocentric comparative cohort study. Sci Rep 10:19337. https:\/\/doi.org\/10.1038\/s41598-020-76551-y","journal-title":"Sci Rep"},{"key":"6254_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00417-019-04272-8","volume":"257","author":"MA Teus","year":"2019","unstructured":"Teus MA, Paz Moreno-Arrones J, Casta\u00f1o B et al (2019) Optical coherence tomography analysis of filtering blebs after long-term, functioning trabeculectomy and XEN\u00ae stent implant. Graefes Arch Clin Exp Ophthalmol 257:1005\u20131011. https:\/\/doi.org\/10.1007\/s00417-019-04272-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6254_CR21","doi-asserted-by":"publisher","unstructured":"Bui TT, Rosdahl JA (2022) Systematic review of MIGS and Non-penetrating glaucoma procedures for uveitic glaucoma. Seminophthalmol 1\u20139. https:\/\/doi.org\/10.1080\/08820538.2022.2102927","DOI":"10.1080\/08820538.2022.2102927"},{"key":"6254_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/biology10040273","volume":"10","author":"M Schargus","year":"2021","unstructured":"Schargus M, Busch C, Rehak M et al (2021) Functional monitoring after Trabeculectomy or XEN Microstent implantation using spectral domain optical coherence tomography and visual field indices\u2014A retrospective comparative cohort study. Biology 10:273. https:\/\/doi.org\/10.3390\/biology10040273","journal-title":"Biology"},{"key":"6254_CR23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.ophtha.2017.05.004","volume":"124","author":"MB Schlenker","year":"2017","unstructured":"Schlenker MB, Gulamhusein H, Conrad-Hengerer I et al (2017) Efficacy, safety, and risk factors for failure of standalone ab Interno gelatin Microstent implantation versus standalone Trabeculectomy. Ophthalmology 124:1579\u20131588. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.004","journal-title":"Ophthalmology"},{"key":"6254_CR24","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00417-019-04341-y","volume":"257","author":"MT Marcos Parra","year":"2019","unstructured":"Marcos Parra MT, Salinas L\u00f3pez JA, L\u00f3pez Grau NS et al (2019) XEN implant device versus trabeculectomy, either alone or in combination with phacoemulsification, in open-angle glaucoma patients. Graefes Arch Clin Exp Ophthalmol 257:1741\u20131750. https:\/\/doi.org\/10.1007\/s00417-019-04341-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6254_CR25","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1177\/11206721221093828","volume":"32","author":"P Marolo","year":"2022","unstructured":"Marolo P, Reibaldi M, Fallico M et al (2022) Reintervention rate in glaucoma filtering surgery: A systematic review and meta-analysis. Eur J Ophthalmol 32:2515\u20132531. https:\/\/doi.org\/10.1177\/11206721221093828","journal-title":"Eur J Ophthalmol"},{"key":"6254_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00417-018-3899-7","volume":"256","author":"RA Widder","year":"2018","unstructured":"Widder RA, Dietlein TS, Dinslage S et al (2018) The XEN45 Gel Stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profile, and rates of re-surgery after 261 surgeries. Graefes Arch Clin Exp Ophthalmol 256:765\u2013771. https:\/\/doi.org\/10.1007\/s00417-018-3899-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6254_CR27","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.18240\/ijo.2018.12.11","volume":"11","author":"AL Bas\u00edlio","year":"2018","unstructured":"Bas\u00edlio AL, Moura-Coelho N, Passos I et al (2018) XEN\u00ae implant and trabeculectomy medium-term quality of life assessment and comparison of results. Int J Ophthalmol 11:1941\u20131944. https:\/\/doi.org\/10.18240\/ijo.2018.12.11","journal-title":"Int J Ophthalmol"},{"key":"6254_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02368-w","author":"G Triolo","year":"2022","unstructured":"Triolo G, Wang J, Aguilar-Munoa S et al (2022) Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes. Eye. https:\/\/doi.org\/10.1038\/s41433-022-02368-w","journal-title":"Eye"},{"key":"6254_CR29","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1080\/09273948.2018.1517892","volume":"27","author":"R Chhabra","year":"2019","unstructured":"Chhabra R, Tan SZ, Au L et al (2019) Long-term outcomes and complications of Baerveldt glaucoma drainage implants in adults with glaucoma secondary to uveitis. Ocul Immunol Inflamm 27:1322\u20131329. https:\/\/doi.org\/10.1080\/09273948.2018.1517892","journal-title":"Ocul Immunol Inflamm"},{"key":"6254_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00417-018-4156-9","volume":"257","author":"WD Ramdas","year":"2019","unstructured":"Ramdas WD, Pals J, Rothova A, Wolfs RCW (2019) Efficacy of glaucoma drainage devices in uveitic glaucoma and a meta-analysis of the literature. Graefes Arch Clin Exp Ophthalmol 257:143\u2013151. https:\/\/doi.org\/10.1007\/s00417-018-4156-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6254_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5005\/jp-journals-10078-1306","volume":"15","author":"N Ventura-Abreu","year":"2021","unstructured":"Ventura-Abreu N, Mendes-Pereira J, Pazos M et al (2021) Surgical approach and outcomes of uveitic glaucoma in a tertiary hospital. J Curr Glaucoma Pract 15:52\u201357. https:\/\/doi.org\/10.5005\/jp-journals-10078-1306","journal-title":"J Curr Glaucoma Pract"},{"key":"6254_CR32","doi-asserted-by":"publisher","unstructured":"Cazana IM, B\u00f6hringer D, Reinhard T, et al (2022) A comparison of long-term results after Baerveldt 250 implantation in advanced uveitic vs. other forms of glaucoma. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-022-05612-x","DOI":"10.1007\/s00417-022-05612-x"},{"key":"6254_CR33","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/IJG.0000000000001583","volume":"29","author":"S Sinha","year":"2020","unstructured":"Sinha S, Ganjei AY, McWatters Z et al (2020) Ahmed versus baerveldt glaucoma drainage device in uveitic glaucoma: A retrospective comparative study. J Glaucoma 29:750\u2013755. https:\/\/doi.org\/10.1097\/IJG.0000000000001583","journal-title":"J Glaucoma"},{"key":"6254_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000505491","volume":"6","author":"KJ Schoelles","year":"2020","unstructured":"Schoelles KJ, Anton A, Auw-Haedrich C (2020) Chronic granulomatous inflammation after CyPass\u00ae implantation. Ocul Oncol Pathol 6:259\u2013264. https:\/\/doi.org\/10.1159\/000505491","journal-title":"Ocul Oncol Pathol"},{"key":"6254_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-022-05767-7","author":"KJ Habbe","year":"2022","unstructured":"Habbe KJ, Kohlhaas M, Langwieder C, Fili S (2022) Foreign body reaction after CyPass\u00ae Micro-Stent implantation: a case series. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-022-05767-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6254_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s10384-021-00864-2","volume":"65","author":"K Matsushita","year":"2021","unstructured":"Matsushita K, Kawashima R, Kawasaki R, Nishida K (2021) Prognostic factors for successful Baerveldt glaucoma implant surgery for refractory glaucoma after multiple surgeries. Jpn J Ophthalmol 65:820\u2013826. https:\/\/doi.org\/10.1007\/s10384-021-00864-2","journal-title":"Jpn J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06254-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T14:08:10Z","timestamp":1709302090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06254-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6254"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06254-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Freiburg and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Approval was granted by the Ethics Committee of the University of Freiburg (No 21-1202_02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient consent was waived, because it was not required by law for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"CE has received a travel grant and JL has received honorary from Allergan\/Abbvie.All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}